{
    "key_points": [
        "WHO has listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use.",
        "The vaccines are produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India.",
        "Emergency Use Listing (EUL) is crucial for COVAX Facility vaccine supply and allows countries to expedite regulatory approval.",
        "Dr Mari\u00e2ngela Sim\u00e3o, WHO Assistant-Director General, emphasizes the importance of equitable vaccine distribution.",
        "The EUL process requires vaccine developers to submit full data for a rapid assessment by WHO.",
        "The AstraZeneca/Oxford vaccines' EUL process took under four weeks after assessment of various data and manufacturing site inspections.",
        "SAGE recommends the AstraZeneca/Oxford vaccine for everyone aged 18 and above.",
        "The vaccine, ChAdOx1-S, has been found to have a 63.09% efficacy and is suitable for low- and middle-income countries.",
        "The EUL procedure aims to make health products available rapidly during emergencies while ensuring safety, efficacy, and quality.",
        "The Pfizer/BioNTech vaccine was also listed by WHO for emergency use on 31 December 2020."
    ],
    "spokespersons": [
        "Dr Mari\u00e2ngela Sim\u00e3o (WHO Assistant-Director General for Access to Medicines and Health Products)"
    ],
    "article_type": "general reporting",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}